These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 18771667)

  • 21. Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads of serum HCV RNA genotype 1b.
    Sasase N; Kim SR; Kudo M; Kim KI; Taniguchi M; Imoto S; Mita K; Hayashi Y; Shoji I; El-Shamy A; Hotta H
    Intervirology; 2010; 53(1):49-54. PubMed ID: 20068341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
    Yenice N; Mehtap O; Gümrah M; Arican N
    Turk J Gastroenterol; 2006 Jun; 17(2):94-8. PubMed ID: 16830289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Early virologic response in retherapy with pegylated interferon alpha-2B plus ribavirin in children with chronic hepatitis C].
    Pawłowska M; Palewicz E; Halota W
    Przegl Epidemiol; 2006; 60(1):71-7. PubMed ID: 16758742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
    J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.
    Vispo E; Barreiro P; Pineda JA; Mira JA; Maida I; Martín-Carbonero L; Rodríguez-Nóvoa S; Santos I; López-Cortes LF; Merino D; Rivero A; Soriano V
    Antivir Ther; 2008; 13(3):429-37. PubMed ID: 18572756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
    Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
    Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
    J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.
    Crespo M; Mira JA; Pineda JA; Van den Eynde E; Ríos-Villegas MJ; Collado A; Girón-González JA; López-Cortés LF; González-Serrano M; Rivero A; Merino D; Esteban JI
    J Antimicrob Chemother; 2008 Oct; 62(4):793-6. PubMed ID: 18567911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
    Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
    Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination therapy with silibinin, pegylated interferon and ribavirin in a patient with hepatitis C virus genotype 3 reinfection after liver transplantation: a case report.
    Knapstein J; Wörns MA; Galle PR; Zimmermann T
    J Med Case Rep; 2014 Jul; 8():257. PubMed ID: 25047566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy.
    Eurich D; Bahra M; Berg T; Boas-Knoop S; Biermer M; Neuhaus R; Neuhaus P; Neumann U
    Exp Clin Transplant; 2011 Feb; 9(1):1-6. PubMed ID: 21605016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy.
    Steindl-Munda P; Ferenci P; Brunner H; Nachbaur K; Datz C; Gschwantler M; Hofer H; Stauber R; Hackl F; Jessner W; Rosenbeiger M; Gangl A; Vogel W;
    Liver Int; 2003 Aug; 23(4):269-75. PubMed ID: 12895267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effects of supplementation with the antioxidant flavonoid, silymarin, in chronic hepatitis C patients treated with peg-interferon + ribavirin. A placebo-controlled double blind study].
    Pár A; Roth E; Miseta A; Hegedüs G; Pár G; Hunyady B; Vincze A
    Orv Hetil; 2009 Jan; 150(2):73-9. PubMed ID: 19103558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C: CIFN for re-treatment of PEG-IFN plus RBV nonresponders?
    Trepo C; Pradat P
    Nat Rev Gastroenterol Hepatol; 2009 Oct; 6(10):570-1. PubMed ID: 19789573
    [No Abstract]   [Full Text] [Related]  

  • 36. Vitiligo improvement in a hepatitis C patient after treatment with PEG-interferon alpha-2a and ribavirin: a case report.
    Taffaro M; Pyrsopoulos N; Cedron H; Cacayorin E; Weppler D; Moon J; Nishida S; Levi D; Kato T; Selvaggi G; Tzakis A; Schiff E
    Dig Dis Sci; 2007 Dec; 52(12):3435-7. PubMed ID: 17431776
    [No Abstract]   [Full Text] [Related]  

  • 37. Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.
    Dahari H; Shteingart S; Gafanovich I; Cotler SJ; D'Amato M; Pohl RT; Weiss G; Ashkenazi YJ; Tichler T; Goldin E; Lurie Y
    Liver Int; 2015 Feb; 35(2):289-94. PubMed ID: 25251042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding silibinin's modes of action against HCV using viral kinetic modeling.
    Guedj J; Dahari H; Pohl RT; Ferenci P; Perelson AS
    J Hepatol; 2012 May; 56(5):1019-1024. PubMed ID: 22245888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.
    DebRoy S; Hiraga N; Imamura M; Hayes CN; Akamatsu S; Canini L; Perelson AS; Pohl RT; Persiani S; Uprichard SL; Tateno C; Dahari H; Chayama K
    J Viral Hepat; 2016 Sep; 23(9):708-17. PubMed ID: 27272497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment options for patients with chronic hepatitis C not responding to initial antiviral therapy.
    Jacobson IM
    Clin Gastroenterol Hepatol; 2009 Sep; 7(9):921-30. PubMed ID: 19362605
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.